In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy. Patients received 2 phases of induction and, if in remission, were assigned...

书目详细资料
Main Authors:	Goldstone, A, Richards, S, Lazarus, H, Tallman, MS, Buck, G, Fielding, A, Burnett, A, Chopra, R, Wiernik, P, Foroni, L, Paietta, E, Litzow, MR, Marks, D, Durrant, J, McMillan, A, Franklin, I, Luger, S, Ciobanu, N, Rowe, J
格式:	Journal article
语言:	English
出版:	2008

相似书籍

The outcome of 551 1(st) CR transplants in adult ALL from the UKALL XII/ECOG 2993 study
由: Goldstone, A, et al.
出版: (2004)

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
由: Fielding, A, et al.
出版: (2007)

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.
由: Sive, J, et al.
出版: (2012)

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
由: Rowe, J, et al.
出版: (2008)

Induction therapy for adults with acute lymphoblastic leukemia (ALL): Results of nearly 1,400 patients from the international ALL trial (MRC UKALL XII/ECOG E2993).
由: Rowe, J, et al.
出版: (2003)

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
由: Rowe, J, et al.
出版: (2005)

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.
由: Lazarus, H, et al.
出版: (2006)

Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).
由: Goldstone, A, et al.
出版: (1999)

Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the international ALL trial (MRC UKALL-XII/ECOG E2993)
由: Lazarus, H, et al.
出版: (2004)

Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993).
由: Rowe, J, et al.
出版: (2001)

Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial.
由: Chopra, R, et al.
出版: (2003)

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.
由: Paietta, E, et al.
出版: (2008)

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
由: Fielding, A, et al.
出版: (2009)

Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph plus) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993).
由: Goldstone, A, et al.
出版: (2001)

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
由: Ganzel, C, et al.
出版: (2020)

Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII.
由: Kumar, A, et al.
出版: (2016)

The impact of imatinib therapy on adult Philadelphia positive acute lymphoblastic leukaemia (ALL): Early results from the UKALL12/ECOG 2993 study
由: Patel, B, et al.
出版: (2005)

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
由: Marks, D, et al.
出版: (2009)

The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years.
由: Goldstone, A, et al.
出版: (2003)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.
由: Moorman, A, et al.
出版: (2007)

Minimal residual disease is a significant predictor of treatment failure in B lineage adult ALL: final results of the international trial UKALL XII:ECOG 2993
由: Patel, B, et al.
出版: (2009)

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
由: Fielding, A, et al.
出版: (2014)

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
由: Fielding, A, et al.
出版: (2010)

Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
由: Fielding, A, et al.
出版: (2010)

Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
由: Fielding, A, et al.
出版: (2010)

Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
由: Mansour, MR, et al.
出版: (2009)

Does imatinib change the outcome in philapdelphia chromosome positive acute lympooblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study
由: Fielding, A, et al.
出版: (2007)

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukaemia (ALL): Analysis of cytogenetic data from 1,235 patients on the medical research council (MRC) UKALLXII/Eastern cooperative oncology group (ECOG) 2993 trial.
由: Moorman, A, et al.
出版: (2005)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
由: Sive, J, et al.
出版: (2010)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL) Results From the International MRC/ECOG Trial
由: Sive, J, et al.
出版: (2010)

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial
由: Sive, J, et al.
出版: (2010)

Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol.
由: Mansour, MR, et al.
出版: (2008)

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993.
由: Patel, B, et al.
出版: (2010)

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial
由: David I. Marks, et al.
出版: (2013-06-01)

The value of molecular monitoring for residual disease (MRD) in early morphological remitters among adults diagnosed with B cell ALL and treated according to the MRC UKALL12 protocol.
由: Foroni, L, et al.
出版: (2005)

Molecular monitoring of residual disease (MRD) during induction and intensification phases in low risk adult B cell ALL treated according to the MRC UKALL12 protocol.
由: Foroni, L, et al.
出版: (2005)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups
由: Lrrzow, MR, et al.
出版: (2010)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups
由: Lrrzow, MR, et al.
出版: (2010)

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lyrnphoblastic Leukemia (B ALL) Patients (pts) From the International UKALLXII/E2993 Trial No Difference In Results Between B Cell Immuno phenotypic Subgroups
由: Lrrzow, MR, et al.
出版: (2010)

Outcome in Philadelphia Chromosome Positive (Ph plus ) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se
由: Paietta, E, et al.
出版: (2008)